Table 1 –
Baseline characteristics and treatment information for all patients and by type of dedifferentiation present
| Met. sRCC (n = 78) | Met. rRCC (n = 49) | Met. S + R RCC (n = 30) | Total (n = 157) | Upfront CN (n = 89) | Deferred CN (n = 29) | No CN (n = 39) | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Age at diagnosis (yr), median (range) | 57 (35–73) | 60 (36–84) | 56 (37–74) | 58 (35–84) | 57 (37–74) | 57 (35–84) | 57 (36–75) |
| Sex, n (%) | |||||||
| Male | 64 (82.1) | 37 (75.5) | 21 (70) | 122 (77.7) | 66 (74.2) | 25 (86.2) | 31 (79.5) |
| Female | 14 (17.9) | 12 (24.5) | 9 (30) | 35 (22.3) | 23 (25.8) | 4 (13.8) | 8 (20.5) |
| Primary epithelial histology, n (%) | |||||||
| Clear cell | 62 (79.5) | 48 (98.0) | 29 (96.7) | 139 (88.5) | 79 (88.8) | 27 (93.1) | 33 (84.6) |
| Papillary | 1 (1.3) | 0 (0) | 0 (0) | 1 (0.6) | 1 (1.1) | 0 | 0 |
| Chromophobe | 5 (6.4) | 0 (0) | 0 (0) | 5 (3.2) | 4 (4.5) | 0 | 1 (2.6) |
| Unclassified | 9 (11.5) | 1 (2.0) | 1 (3.3) | 11 (7.0) | 4 (4.5) | 2 (6.9) | 5 (12.8) |
| MTSC | 1 (1.3) | 0 (0) | 0 (0) | 1 (0.6) | 1 (1.1) | 0 | 0 |
| No. of metastases at ICT, n (%) | |||||||
| 1 | 11 (14.1) | 9 (18.4) | 6 (20.0) | 26 (16.5) | 13 (14.6) | 7 (24.1) | 6 (15.4) |
| 2–3 | 31 (39.7) | 38 (77.5) | 13 (43.3) | 82 (52.2) | 45 (50.6) | 16 (55.2) | 21 (53.8) |
| ≥4 | 36 (46.2) | 2 (4.1) | 11 (36.7) | 49 (31.2) | 31 (34.8) | 6 (20.7) | 12 (30.8) |
| Systemic therapies before ICT, n (%) | |||||||
| 0 | 47 (60.2) | 34 (69.4) | 21 (70.0) | 102 (65.0) | 45 (50.6) | 25 (86.2) | 32 (82.0) |
| 1 | 23 (29.5) | 12 (24.5) | 7 (23.3) | 42 (26.8) | 32 (36.0) | 4 (13.8) | 6 (15.4) |
| ≥2 | 8 (10.3) | 3 (6.1) | 2 (6.7) | 13 (8.2) | 12 (13.4) | 0 | 1 (2.6) |
| Type of ICT received, n (%) | |||||||
| Nivolumab + ipilimumab | 32 (41.0) | 19 (38.8) | 13 (43.3) | 64 (40.8) | 26 (29.2) | 17 (58.6) | 23 (59.0) |
| ICT + TKI | 19 (24.4) | 15 (30.6) | 9 (30.0) | 43 (27.4) | 28 (31.5) | 7 (24.1) | 9 (23.0) |
| ICT monotherapy | 26 (33.3) | 11 (22.4) | 7 (23.3) | 44 (28.0) | 32 (36.0) | 5 (17.3) | 7 (18.0) |
| ICT + other | 1 (1.3) | 4 (8.2) | 1 (3.3) | 6 (3.8) | 3 (3.3) | 0 | 0 |
| IMDC risk score at ICT initiation, n (%) | |||||||
| Favorable | 8 (10.3) | 2 (4.1) | 5 (16.7) | 15 (9.6) | 13 (14.6) | 1 (3.5) | 1 (2.6) |
| Intermediate | 44 (56.4) | 30 (61.2) | 11 (36.7) | 85 (54.1) | 47 (52.8) | 17 (58.6) | 19 (48.7) |
| Poor | 26 (33.3) | 17 (34.7) | 14 (46.6) | 57 (36.3) | 29 (32.6) | 11 (37.9) | 19 (48.7) |
| Nephrectomy, n (%) | |||||||
| Yes | 55 (70.5) | 35 (71.4) | 28 (93.3) | 118 (75.2) | |||
| No | 23 (29.5) | 14 (28.6) | 2 (6.7) | 39 (24.8) | |||
| Time of nephrectomy, n (%) | |||||||
| Upfront CN | 43 (78.2) | 27 (77.1) | 19 (67.9) | 89 (75.4) | |||
| Deferred CN | 12 (21.8) | 8 (22.9) | 9 (32.1) | 29 (24.6) | |||
| Charlson comorbidity index, n (%) | |||||||
| 6 | 17 (21.8) | 7 (14.3) | 5 (16.7) | 29 (18.5) | 17 (19.1) | 7 (24.1) | 5 (12.8) |
| 7–8 | 43 (55.1) | 29 (59.2) | 16 (53.3) | 88 (56.0) | 53 (59.6) | 15 (51.8) | 20 (51.3) |
| ≥9 | 18 (23.1) | 13 (26.5) | 9 (30.0) | 40 (25.5) | 19 (21.3) | 7 (24.1) | 14 (35.9) |
CN = cytoreductive nephrectomy; ICT = immune checkpoint therapy; IMDC = International Metastatic RCC Database Consortium; Met. = metastatic; MTSC = mucinous tubular and spindle cell carcinoma; RCC = renal cell carcinoma; rRCC = rhabdoid renal cell carcinoma; S + R = sarcomatoid plus rhabdoid; sRCC = sarcomatoid renal cell carcinoma; TKI = tyrosine kinase inhibitor.